Corvus Pharmaceuticals CRVS PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's PP&E (net)?
- Corvus Pharmaceuticals (CRVS) reported PP&E (net) of $282K in Q1 2026.
- How has Corvus Pharmaceuticals's PP&E (net) changed year-over-year?
- Corvus Pharmaceuticals's PP&E (net) increased by 70.9% year-over-year, from $165K to $282K.
- What is the long-term trend for Corvus Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's PP&E (net) has grown at a -24.7% compound annual growth rate (CAGR), from $906K to $220K.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.